🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Impact of APP-assisted Patient Management on the Quality Control of Blood Purification Therapy

RecruitingNAAges 18 Years - 75 YearsAllYunfeng Xia
NCT07291154 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Many maintenance hemodialysis (MHD) patients develop negative outlooks due to their illnesses and complications, making their quality of life and prognosis a clinical concern. Effective life management and treatment cooperation are crucial to improving dialysis quality and patient outcomes. This trial aims to evaluate whether management through the "Yueya" mini-program and WeChat can provide personalized guidance such as health education, diet, exercise, medication supervision, and condition monitoring to enhance treatment compliance, quality of life, strengthen quality control in the hemodialysis unit, and improve patient prognosis. Patients will be divided into a group receiving support via the "Yueya" mini-program and WeChat, and a control group receiving routine care. Clinical and laboratory indicators, cardiovascular events, death, hospitalization, quality of life, and compliance w

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients with stage 5 chronic kidney disease, who have received maintenance hemodialysis for more than 3 months, are aged between 18 and 75 years old, and have regular dialysis three times a week. * Patients with relatively stable condition, who are able to take care of themselves and willing to cooperate with the study. * Patients who can understand and proficiently use WeChat and the "Yueya" mini - program used in this study. Exclusion Criteria: * Patients with communication barriers or other conditions that prevent them from cooperating with the study. * Patients who have a history of acute myocardial infarction, cerebral infarction or intracerebral hemorrhage in the past six months. * Patients who are not willing to actively cooperate with the study. * Patients with severe liver cirrhosis, active tuberculosis and AIDS.
💊

What it tests

  • APP-based management
📍

Where

1 site
The First Affiliated Hospital of Chongqing Medical University
Chongqing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy